EPRX ▲ +2.0% - Eupraxia Pharmaceuticals Inc.
$EPRX - Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
30-SEP-2026 08:01 AM ET
Share this post
More filings for $EPRX
EPRX ▼ -4.4% - Eupraxia Pharmaceuticals Inc.Oct 15, 2026EPRX - Eupraxia Pharmaceuticals Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026
View full $EPRX filing history →💬 Comments
Loading comments…
Leave a comment